Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Fig. 4

Lower expression of hsa-miR-181a-5p of 0.43 was also observed in Group 2 (CML patients non-responsive to imatinib therapy) compared with the Control Group (blood donors) by real-time RT-qPCR (p-value < 0.05). In addition, higher expressions were only observed from hsa-miR-182-5p and hsa-miR-26a-5p of 2.08 and 2.39, respectively, in this group

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us